Mettler-Toledo International Inc (MTD) 2021 Q4 法說會逐字稿

Good day, and thank you for standing by. Welcome to the Mettler-Toledo Quarterly Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Ms. Mary Finnegan. Please go ahead.

Thank you, and good evening, everyone. I'm Mary Finnegan. I'm responsible for Investor Relations at Mettler-Toledo and happy that you're joining us this evening. I'm joined on the call today with Patrick Kaltenbach, our CEO; and Shawn Vadala, our Chief Financial Officer.

Let me cover just a couple of administrative matters. This call is being webcast and is available on our website. A copy of the press release and the presentation that we refer to on today's call is also on the website.

Let me summarize the safe harbor language, which is outlined on Page 2 of the presentation. Statements in this presentation, which are not historical facts, constitute forward-looking statements within the meaning of the U.S. Securities Act of 1933 and the U.S. Securities Exchange Act of 1934. These statements involve risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements.

For a discussion of these risks and uncertainties, please see the discussion in our recent Form 10-K and other reports filed with the SEC from time-to-time. All of the forward-looking statements are qualified in their entirety by reference to the factors discussed under the captions Factors Affecting Our Future Operating Results and the Business and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our filings.

One other item. On today's call, we may use non-GAAP financial measures. More detailed information with respect to the use of and differences between the non-GAAP financial measure and the most directly comparable GAAP measure is provided in the 8-K.

Let me now turn the call over to Patrick.

Thanks, Mary, and good evening, everyone. We had a great finish to 2021 with strong fourth quarter results. We capitalized on robust customer demand and executed very well, particularly with respect to our supply chain to meet customer demands. The strength and agility of the teams around the world are reflected in these results.

The highlights of the quarter are on Page 3 of the presentation. Local currency sales growth was 11%, and we had particular strong growth in the Americas and Asia and Rest of the World. Both our Laboratory and Industrial product lines performed very well. As expected, Food Retail was a headwind to our overall sales growth as we again had a significant decline in the quarter.

Despite facing higher material and transportation costs due to challenges in the supply chain, we had very solid growth in adjusted operating profit and strong growth in adjusted EPS in the quarter.

The fourth quarter was the end to an excellent year of results. For the full year, we achieved an 18% increase in local currency sales, a 26% increase in adjusted operating profit, which resulted in a margin improvement of 130 basis points. We had adjusted -- we had outstanding 32% growth in adjusted EPS. And finally, cash flow generation in 2021 was excellent.

We not only achieved great results, we also strengthened our competitive position in 2021 as innovation nourished our excellent product portfolio and comprehensive services offering combined with our Spinnaker sales and marketing strategies helped us capture growth opportunities.

We also did a superb job navigating the hurdles in the global supply chain. Our agility and excellent execution further reinforced our already strong brand. Importantly, our impressive results last year allowed us to make important investments for future growth. We are confident in our ability to continue to gain share and believe we are ideally positioned to deliver strong results in 2022 and beyond.

I will have some additional comments later, but let me turn it first to Shawn to cover the financial results. Shawn?

Thanks, Patrick, and good evening, everyone. Sales in the quarter were $1.037 billion. This represents our first $1 billion quarter, which was a nice way to end 2021. This represented a local currency increase of 11%. On a U.S. dollar basis, sales also increased 11%.

The PendoTECH acquisition contributed approximately 1% to local currency sales growth in the quarter, while we estimate that the impact of reduced volume of pipette tips in COVID testing was a headwind of approximately 1% to sales growth in the fourth quarter.

On Slide #4, we show sales growth by region. Local currency sales increased 16% in the Americas, 4% in Europe and 14% in Asia/Rest of the World. Local currency sales increased 12% in China in the fourth quarter.

The next slide shows sales growth by region for the full year 2021. Local currency sales grew 18% in 2021, with a 20% increase in the Americas, 12% in Europe and 21% growth in Asia/Rest of World. Local currency sales increased 25% in China for the full year.

On Slide #6, we summarize local currency sales growth by product area. For the fourth quarter, Laboratory sales increased 15%; Industrial increased 11%, with core industrial up 11% and product inspection up 10%. Food Retail declined 20% in the quarter.

The next slide shows local currency sales growth by product area for the full year 2021. Laboratory sales increased 22%. Industrial increased 15%, with core industrial up 18% and product inspection up 10%. Food Retail declined 6% in 2021.

Let me now move to the rest of the P&L for the fourth quarter, which is summarized on Slide #8. Gross margin in the quarter was 58.5%. We benefited from volume and pricing, which was offset by challenges in the global supply chain, namely higher material and transportation costs as well as the impact of temporary cost actions we undertook in 2020.

R&D amounted to $45.6 million in the quarter, which is a 14% increase in local currency over the prior period. The impact of temporary cost savings undertaken last year and greater project activity contributed to this increase.

SG&A amounted to $242.4 million, an 8% increase in local currency over the prior year. The impact of the temporary cost savings that we undertook last year, higher variable compensation and increased investments in sales and marketing were the principal factors driving the increase.

Adjusted operating profit amounted to $319.1 million in the quarter, a 9% increase over the prior year amount of $292.8 million. The increase reflects strong sales growth combined with good execution. Adjusted operating margins were 30.8% and were impacted by higher costs associated with our global supply chain and transportation costs.

A couple of final comments on the P&L. Amortization amounted to $16.9 million in the quarter. Interest expense was $11.5 million in the quarter. Other income, excluding onetime items in the quarter, amounted to $5.3 million, primarily reflecting nonservice-related pension income.

We reduced our effective tax rate from 19.5% to 19.0% in the quarter. This rate is before discrete items and adjusting for the timing of stock option exercises in the quarter. We're pleased with this reduction and expect to maintain the 19% rate in 2022. Fully diluted shares amounted to 23.2 million in the quarter, which is a 3% decline from the prior year.

Adjusted EPS for the quarter was $10.53, a 14% increase over the prior year amount of $9.26. On a reported basis in the quarter, EPS was $9.94 as compared to $9.03 in the prior year. Reported EPS in the quarter includes $0.21 of purchased intangible amortization and $0.09 of restructuring.

We also had 2 items impacting income taxes. We had $0.17 of cost due to the difference between our quarterly and annual tax rate due to the timing of stock option exercises. And we had a $0.14 benefit from adjusting our tax rate to 19% for the first 3 quarters.

Finally, we had a $0.26 acquisition charge primarily -- principally reflecting an increase for the PendoTECH acquisition earnout due to their updated projections.

The next slide shows our P&L year-to-date. As Patrick mentioned, we had an exceptional year of results in 2021, with local currency sales growth of 18% and adjusted operating profit increase of 26% and our operating margins increasing 130 basis points to 28.5%.

Finally, adjusted EPS grew 32% to $34.01 in 2021. We're extremely pleased with these results and our ability to capitalize on growth opportunities and navigate a challenging supply chain environment.

That covers the P&L, and let me now comment on cash flow. In the quarter, adjusted free cash flow amounted to $206.6 million, which was better than what we had expected and was impacted by the timing of tax payments. DSO showed further improvement in the quarter with a decline of 2 days to 35 days as compared to the prior year. ITO came in at 4.3x, flat with the prior year.

For the full year, adjusted free cash flow amounted to $821.9 million, an increase of 31% on a per share basis as compared to the prior year. The strength of our cash flow is apparent in our net income conversion, which reached 103% in 2021.

Let me now turn to guidance. Forecasting remains challenging. Demand in our end markets is favorable, although there are pockets of uncertainty in the global economy, particularly in China. The challenges within the global supply chain and in transportation and logistics and the corresponding inflationary impact also creates uncertainty.

Finally, we acknowledge that COVID is not behind us and variants and lockdowns can occur quickly. We recognize the importance of remaining agile and adapting to unexpected changes in the environment. We remain cautious about factors outside of our control and remain focused on our growth initiatives. We believe we can continue to gain market share and drive margin improvement via our pricing and SternDrive initiatives.

Now let me cover the specifics. For the full year 2022, we now expect local currency sales growth to be approximately 7%. This compares to previous guidance of 6%. We expect full year adjusted EPS to be in the range of $38.15 to $38.50, which is a growth rate of 12% to 13%. This compares to previous guidance of adjusted EPS in the range of $37.25 to $37.65.

Some additional comments on 2022 guidance. We expect a slight headwind to sales growth from the impact of COVID testing on our pipette business. We expect gross margins for the full year to increase in the 30 to 40 basis point range. However, we expect to see improvement in gross margins in the second half of the year as we see further benefit in pricing and other margin initiatives.

Interest expense is estimated at approximately $50 million; and total amortization, including purchased intangible amortization, to be $67 million. Purchased intangible amortization is excluded from adjusted EPS and is estimated at $25 million on a pretax or $0.86 per share. Other income, which is below operating profit, is estimated at approximately $14 million. Finally, as I already mentioned, we expect our effective annual tax rate before discrete items will be 19%.

Turning to the first quarter. Based on market conditions today, we expect local currency sales growth of approximately 10% and expect adjusted EPS to be in the range of $7.25 to $7.35, a growth rate of 11% to 12%.

A couple of further comments. A reminder that comparisons in the first quarter are particularly challenging as adjusted EPS grew more than 60% in Q1 last year. We would expect gross margins to be down in Q1 due to higher supply chain and transportation costs. We'll provide more insight on our next call, but it's worth mentioning now, as you update your models, that Q2 will have a very tough prior year comparison as local currency sales were up 27% and adjusted EPS increased more than 50% in the second quarter of last year.

Some final details on guidance. With respect to the impact of currency and sales growth, we expect currency to decrease sales growth by approximately 1% in 2022 and decrease it by 2% in Q1. In terms of adjusted EPS, currency is a little worse than the last time we provided guidance. We now expect currency will be a headwind to adjusted EPS growth of approximately 1% in 2022 and a headwind of approximately 2% in the first quarter.

Let me comment on free cash flow. For the full year 2022, we estimate it will reach $855 million. As we mentioned on our last call, our cash flow this year is impacted by higher variable compensation payments related to the very strong performance in 2021. In fact, we expect cash flow in Q1 to be down versus the prior year. Once we get beyond 2022, we expect free cash flow per share will grow in line with earnings per share and net income conversion will be in the 100% range.

We expect to repurchase approximately $1 billion in shares in 2022, which should allow us to maintain a net debt-to-EBITDA leverage ratio of approximately 1.5x.

That is it from my side, and I'll now turn it back to Patrick.

Thanks, Shawn. Let me start with some comments on our operating results. Our Lab business had very strong growth in the quarter despite having great growth in the prior year. Almost all product lines showed robust growth.

We will start the year with very good momentum in Lab in the first quarter, while growth in the remaining quarters will be impacted by challenging multiyear comparisons. With our excellent product portfolio and effective sales and marketing initiatives, we believe we are well positioned to capture growth and continue to gain market share in our Laboratory business.

Turning to our Industrial business. Core industrial did very well in the quarter and will have a strong start to 2022. We are benefiting from our attractive product portfolio, very good implementation of Spinnaker sales and marketing initiatives as well as increasing demand from our customers for automation and digitalization. We will face tougher comparisons as the year progresses, but expect to continue to gain share here as well.

We are pleased with another quarter of good growth in product inspection, which increased 10% in the quarter. We expect a good start to the year and are optimistic that we will have good growth in 2022 as large packaged food companies show more appetite for investments.

Finally, Food Retail declined 20% in the fourth quarter. We were impacted by shortages of electronic components as well as timing of project activity. We expect low double-digit decline in the first quarter and overall do not expect much growth here in 2022.

Now let me make some additional comments by geography. Sales in Europe increased 4% in the fourth quarter, which was in line with our expectations. Both Lab and Industrial had solid growth, while Retail was down double digits. We expect good growth in Europe to start the year and overall solid growth for the full year 2022.

Americas had another quarter of very strong growth with 16% increase. Lab had excellent growth, while Industrial also did very well. Retail was down significantly. Americas will also have a strong start to the year and then face more challenging comparisons as the year progresses.

Finally, Asia/Rest of World grew 14% in the fourth quarter with outstanding growth in Laboratory and product inspection and very good growth in core industrial. China grew 12% with excellent growth in Lab. We are very strongly positioned in China, and the team continues to execute well.

One final comment on the business. Service and consumables performed really well and were up 10% in the quarter. We continue to be very pleased with the growth in this important and profitable part of the business. That concludes my comments on the business.

While COVID is not yet behind us, we believe we will exit the pandemic in a stronger competitive position. Many factors have contributed to this, including our excellent product portfolio, extensive service offering, well-ingrained and proven sales and marketing strategies and an agile and experienced supply chain team.

Another important factor is our process and system harmonization program, Blue Ocean, which is the foundation and enabler of many of our corporate programs and initiatives. Blue Ocean is a multiyear program that harmonizes how we do business internally and with customers. It encompasses all aspects of our franchise: sales, service, supply chain, R&D, HR and finance. With harmonized processes and data, we can leverage a globally standardized single-instance IT system that digitalizes our processes and provides data that increases our business transparency.

Let me provide some additional insight. Blue Ocean supports the framework for our Spinnaker sales and marketing initiatives. Our CRM and installed base provides extensive details on customers and potential customers that we use in marketing campaigns, sales, project alerts, cross-selling campaigns and support for other data analytics techniques. It provides comprehensive data on customers' purchasing activity.

Blue Ocean is also the foundation for our pricing program. It provides data analytics to guide us in our pricing decisions and also allows us to implement price increases efficiently on a global basis. Similarly, Blue Ocean harmonizes our services offering, allowing us to provide standardized services on a global basis. It also provides transparency in terms of field service productivity, service profitability by customer and highlights additional sales opportunities.

Our supply chain is highly complex as it involves more than 3,000 possible suppliers, 150,000 different SKUs, more than 800,000 components, 19 production organizations and 3 logistic hubs. Blue Ocean provides us with the transparency and real-time data that is critical for navigating supply chain challenges.

Agility and collaboration between our market organizations and business units allow us to leverage our supply chain as a competitive advantage in helping us gain share. Blue Ocean is critical to the success of our SternDrive program as it provides the data and transparency to continually make improvements to our back office and manufacturing productivity.

Finally, Blue Ocean is instrumental in providing meaningful real-time information that has become particularly important during the last 2 years, given how quickly market conditions have been changing. We developed specialized and tailored data alerts, allowing us to see firsthand the impact on our business and allow us to make decisions quickly. We will continue to evolve Blue Ocean and believe it has become a clear competitive advantage for us.

Before I conclude, I also want to make a brief comment on our ESG initiatives. We are committed to sustainable development across the broad environmental, social and governance aspects covered by our long-standing GreenMT sustainability program. We believe it is our responsibility to act in a manner that considers future generations.

We have great accomplishments in ESG, including achieving carbon neutrality with respect to Scope 1 and 2 emissions and sourcing 100% renewable electricity. We focus on 5 key areas: one, environmental; two, sustainable products and services; three, responsible supply chain; four, engaged employees; and five, good corporate governance.

While we have an excellent track record in ESG, we have set ambitious targets for the future. Importantly, we have recently committed to absolute emission reduction targets consistent with the latest criteria issued by the Science Based Targets initiative. This will cover Scope 1, 2 and 3 emissions. We have also set a target to reduce our waste intensity by 20% and achieve 0 waste to landfill by 2025.

To reinforce the importance of ESG, executive management compensation in 2022 will incorporate specific environmental as well as diversity targets. I think both Blue Ocean and our ESG goals are great examples of how Mettler-Toledo focuses on the long term to enhance the value of our franchise.

I would now like the operator to open the call for questions.

(Operator Instructions) Your first question will come from Dan Arias with Stifel.

This is Eric on for Dan. Just one on capital deployment. Could you just discuss your plan for that -- for the year besides the $1 billion share buyback? Like are you finding any assets becoming more attractive, given the recent market moves that might have you looking for one that might be on a larger scale than the usual smaller tuck-in deals?

Yes. Maybe -- so I guess there's 2 parts to that question. So in terms of our M&A strategy, I'll let Patrick kind of comment on that, but no change in our strategy. We still think we're a great platform for bolt-on acquisitions. We also feel very strongly about our organic story. So we're very selective in terms of the acquisitions. But if you look at like the PendoTECH acquisition we did last year, I think that's a really excellent example of the type of acquisition that we're looking for. And PendoTECH, of course, has been a great addition to Mettler-Toledo.

In terms of capital deployment, we also feel good about our share repurchase program. The program continues to be very successful from our perspective. And we target about a 1.5x net leverage ratio. And right now, we're expecting to repurchase about $1 billion of shares in 2022. And as a reminder, we do that on a very consistent basis throughout the year.

Okay. And then could you just provide a rundown of the top line assumptions by segment for the first quarter and for the 2022 that's baked into the improved guide?

Sure. So I'll start with the divisions. So I'll start with the Lab division. Right now, our guidance is low double-digit growth for Q1 and high single-digit growth for the full year. For core industrial, we expect high single-digit growth in Q1 and mid-single-digit growth for the full year. For product inspection, we expect high single-digit growth for Q1 and high single-digit growth for the full year. And for Food Retailing, we expect to be down double digit in Q1, but grow low single digit for the full year.

And then I'll also give you the geographies. For Europe, we expect Q1 to be up mid-single digit to high single digit and for the full year to be up mid-single digit. For the Americas, we expect to grow low double digit in Q1 and grow mid-single digit to high single digit full year. And then for China, we expect to grow approximately 10% Q1 and approximately 10% for the full year.

Your next question will come from the line of Derik De Bruin with Bank of America.

This is Nisarg on for Derik. So geographically, a 2-parter on China here. Are you seeing any impacts in China specifically from lockdowns? And also, trade tensions are heating up with some touching the bioprocessing CDMO segment. Is there any concern that the trade issues could slow demand for Lab products?

Let me take that. Look -- I mean our business in China has been very strong. We have a very strong footprint in China. We have been there for 30 years. We serve many customers in a broad base. Also, as a reminder, more than 40% of our business in China is Industrial business. But to biopharma and what we're seeing there is very healthy trends for us. We have overall not seen impacts from lockdowns in the last quarter. And right now, at least what we are hearing from the team is they are not concerned of any of the impact that you mentioned regarding biopharma right now.

Great. And then one more on the margins for the quarter. What were some of the -- can you go more into detail on some of the pressures you saw? And how do you kind of expect them to impact early on in 2022? Do you think there's going to be any carryover there?

Yes. So I'll take that one. So maybe I'll talk more broadly about the margin and then kind of like then kind of talk about 2022 as well. So as we mentioned in the prepared remarks, our gross margin was down 110 basis points in the quarter. On one hand, we had favorable price realization. Our price realization was just over 3% in the quarter, which would translate to approximately 140 basis point benefit to the margin. Of course, we also benefited from our volume in the quarter.

But the one thing that clearly stood out from our perspective was the higher material costs as well as higher transportation costs in the quarter. And as we kind of like look to Q1, we're expecting to see similar trends overall for gross margin with probably very similar dynamics. Probably that pricing will continue to be in that 3% kind of a range, but we'll still continue to have like a bit of a headwind on material costs and transportation.

So if we look at gross margin for Q1, I wouldn't be surprised if we're down another 100 basis points in Q1. But we still remain very confident about our ability to expand the margin. And so as we look to the full year, we still believe we can expand our gross margin by 30 to 40 basis points. And we expect to still increase our operating margin overall at the higher end of our typical guidance.

So as a reminder, we typically would say, hey, we can expand margins on an annual basis 70 basis points to 100 basis points. If you look at the midpoint of our guidance, we're towards the higher end of the range of that, probably about 90 basis points. So when you break that down, we are expecting a little bit better pricing in 2022 than what we previously expected.

We were previously guiding to about 3% for next year. Right now, we're thinking it will be probably 3.5% or so. And wouldn't be surprised if we get to the 4% kind of a range in the second half of the year because, of course, we're going to continue to adjust and do actions as we see appropriate, especially as we saw some of the pressures in the fourth quarter on our cost structure.

But it's not only about pricing. Of course, we're also going to be doing some things in terms of optimizing our supply chain as we continue to look for opportunities, for example, to reengineer components or look for other sources in the supply chain.

Your next question will come from Josh Waldman with Cleveland Research.

Just a couple for you, Shawn or Patrick. I guess, from a demand outlook perspective, could you talk through the product areas or the regions that improved versus your plan 90 days ago that led you to pull your organic growth up this early in the year?

Maybe I'll start off, Shawn, and let you chime in as well. So let me talk through the product categories. I mean, we see sustained demand, healthy demand in our Lab business moving forward. So we -- and Shawn gave you the numbers in terms of the growth expectations. So Lab, I would say, holds up very strong, has been strong in Q4 already.

We're also pleasantly surprised by the momentum that we still see in Industrial, driven by the demand for automation and digitalization. And our product portfolio that we have there really serves the demand very well. I think I mentioned in my comments also the fact that we're still seeing some healthy appetite in product inspections from some of the packaged food companies out there.

So overall, I would say we are actually, on a broader front across these categories that I just mentioned, really well -- nicely surprised that we see stronger demand than we anticipated when we gave you the last guidance, and that's why we raised the guidance. That's basically -- I wouldn't point to any specific end market here, not to any specific region. I would say, overall, we see better demand than we expected.

Got it. Got it. Then Shawn, I wondered if you could provide us a bridge to the updated earnings guide. I mean it sounds like most of the increase was due to organic growth, I guess. Is that correct? And then if you could provide us kind of your assumptions for the low and the high end of the EPS range as it relates to maybe organic growth and margin, that would be helpful.

Yes. So I'd say if you kind of bridge EPS, like you said, a lot of it has to do with higher sales growth, increasing the sales growth. Of course, we also added in our beat for 2021, which includes a lower tax rate at 19%, and that was offset a little bit by unfavorable currency.

And could you provide the range or the assumptions that went into the range for the updated guide -- EPS guide?

Yes, we typically don't get too much into like the specific assumptions for the low end and the high end. I mean we -- for the top line, for example, we said approximately 7%. So I don't want to try to start deviating from is that 6-point-this or 7-point-that; or on the margins, a little bit lower or a little bit higher. But you could probably flex your model and get a sense for what that would translate in terms of an EPS range.

But you can appreciate, Josh. I mean there's a lot of ingredients into the recipe at this point of time of the year. A lot of things can change as we get into the year. It's a very, very dynamic environment. And so there's always going to be things that can be a little bit better. But there's -- of course, there's things that can be a little bit worse.

Your next question will come from Tycho Peterson with JPMorgan.

This is Rachel on for Tycho. Congrats on the quarter, you guys. So a few questions here on Lab. So Lab was better than expectations. You guys grew about 15% versus guidance of low double digits for 4Q. So can you talk about if you saw any catch-up spending on the Lab side of things? And then were there any other underlying changes in that market to drive the beat there?

No. Look, I wouldn't say there was catch-up or any pent-up demand. We saw -- we see really strong demand for our products. We have a very strong product portfolio. I think it competes extremely well. Right now, we also have been able to deliver to our end customers, and that came to some extent at some cost, as Shawn also mentioned, that drives -- that had a little bit of impact on our gross margin because we do broker buys for chips, et cetera, big components, more expensive. But it's very important for us to really make sure that we can deliver products to our customers.

Overall, I think we see very strong demand for our products, and it's reflected in those numbers. There is not a specific market segment that I would point to. Pharma, biopharma, as we said, is very strong for us for Lab. But it is also, of course, deployed in other segments like even battery segment. Or if you look at the broader chemical segment, of course, all of the labs buy products from us. And there is healthy amount from these end markets. None of them really specifically that sticks out in terms of change versus what we had guided regarding Q4.

Yes. And you can see that strong momentum is also reflected in our Q1 guidance of low double digit for Lab.

Yes. Helpful. And then maybe going off that for the segment guidance. So appreciate the comments around the expectations by geography as well. So it looks like you have an improved outlook in Europe and Americas for the year. So can you just talk about what's driving your confidence in those regions? Is it specific segments that's driving it? Or kind of what drove the increase there?

Yes. So yes, so the Americas, yes, was up a little bit. I mean we just continue to -- I mean you saw what we did in the fourth quarter in the Americas as well. I mean it's just really, not to overuse the word, but really good momentum, very broad-based growth in the portfolio. And that was despite our Food Retailing business being down in the quarter.

I would say our Industrial business is -- our Lab business is doing very well, but our Industrial business continues to be really resilient and performing well. And as Patrick was saying earlier, we very much are benefiting from a lot of these trends towards automation and digitalization. I mean there's just a huge demand in the world to be more productive, and we're just very fortunate to be in a position to be able to help serve that demand.

And the teams have done such a great job in this division. There's a lot of good innovation. There's also really good execution. And as we've been trying to also pivot the business towards the more attractive market segments over the years, we continue to see that paying a lot of dividends. And then also, as Patrick mentioned, there are these hot segments in the world, both on the Lab side and in the Industrial side that we also have been good at in terms of capturing growth.

Your next question will come from Jason Reiver with Citi.

You've got Jason on for Patrick. Two quick questions for you. One, you've seen strength in the industrial market. Just curious about the visibility into that strength into '22. And then two, just wondering on how PendoTECH is performing relative to expectations? And any further color to shed there?

Yes, I'll take it. Good questions on Industrial. I think it is -- as we look into 2022, of course, we will face tougher comparisons, as I said, as we're going deeper into 2022 towards the second half, but we see good demand in end markets. It's driven basically in all major regions by demand for automation and for digitalization. Shawn mentioned that as well. That's the really fundamental driver we have, an outstanding performance platform there on the product side to serve those demands.

And we are confident that also the new products that we launch this year like the Industry360 (sic) [IND360] terminal really addresses these demands nicely. And we think it will continue into 2022. Of course, given that we will have tougher comparisons, you will not see the same growth rates in the second half. But we're competing extremely well there.

On your comment regarding PendoTECH, we are very pleased with that acquisition. Actually, it outperformed our expectations in 2021, and we see continued strong demand as we go into 2022 for the products.

Your next question will come from the line of Jack Meehan with Nephron Research.

Had another question on Industrial, but was hoping you could weigh in. We're seeing higher commodity prices, along with the talk around inflation. I was curious, just from a demand perspective, if you saw that playing out in terms of any of the Industrial customers for your coverage for your -- just amongst your customer base on the Industrial side?

No. Jack, this is Shawn. No, we're not seeing that impact at any of our customer demand at all. Interesting comment, but no, we're not seeing it from the customer side.

Interesting. Okay. And then back on product inspection. So the guide for the first quarter, high singles. The headline looks good. I have that compounding, though, still kind of in the low single digits, given the comps. Just be curious just to get a little bit more color as you're talking with your customers when you think just the timing for when some of the renewed spend could be going into CapEx.

I'm sorry, Jack -- go ahead, Patrick, yes.

Okay, Shawn, I'll take it. Okay. Look, we are really happy with the result of product inspection in Q4, also with the full year results. We are clearly a leader in product inspections. We have the products -- broadest product range and also the largest services network. Our outlook for 2022 is good, and we are assuming that we see more investment from large food manufacturing. So there is some pent-up demand. And that's why we also guided to double-digit growth in the first quarter, and we expect this segment for us to perform really, really well.

But also as a reminder, to understand food manufacturers represent only about 70% of our product inspection business. And these customers have been impacted by COVID. Remember, last year, we talked about the fact that it was also difficult for our service people to get in some of these accounts and deliver services. That is coming back -- has come nicely back. So we will also see better service growth than we had last year in this segment as well.

Your next question will come from the line of Matt Sykes with Goldman Sachs.

Maybe, Patrick, just a high-level one for you. As you think about the supply chain, and you've been dealing with a lot of challenges there, it sounds like you've been making a number of investments in Blue Ocean and other areas to try to improve that. And I'm sure this environment has probably led you to see a number of pressure points that you might be able to alleviate with spend.

But I guess my question is, if we do come out of it and supply chain does start to loosen up, do you feel like the investments that you've made so far will lead to greater efficiencies in productivity and maybe acceleration of margin expansion if we get out of this because of what you've already put into the business to make it better?

Well, look, a very good question, Matt. Thanks. I mean we continuously invest in Blue Ocean since many, many years, right? And we -- right now, about 85% of the overall business is on Blue Ocean. So we still have a couple of roll-ins to do, but we're making good progress there.

Definitely, the investments we're doing are all targeting productivity enhancements across the board. So we will continue to benefit from those. Whether it will be an acceleration of margin improvement, I don't think so. I mean we have a history. We have made all these good improvements in margin expansion, so I wouldn't put that into consideration we move forward.

We will make -- we'll continue to make improvements, but I think we will not see an acceleration just by the fact that we do these investments in Blue Ocean. We have done this in the past. We're making great progress. We are absolutely convinced it is a competitive advantage for us, and it will continue to drive improvement, but not accelerate it.

Got it. And then maybe, Shawn, you had mentioned in your prepared remarks some uncertainty around China, which I think is pretty apparent. So you're looking for sort of 10% growth for the year. Anything that you're concerned about regarding China, underlying that kind of uncertainty comment? Or is it sort of COVID-related, lockdown related type issues?

Yes. I mean we're not seeing anything specific in our business, Matt, but it's just that general knowledge that everyone has about like there's just a lot of things going on there. I mean it could be -- like you said, it could be COVID. It could be lockdowns. The way that they handle COVID with their 0 tolerance policy could have implications on the business or in the local economy. PMIs have been floating right around 50% on and off.

But there's always uncertainty there. And then there's always -- and we always say things can change quickly there, right? They can go in either direction very quickly, and that's always been our history there. So I think for us, it's always important to remind people that when we give guidance, to provide that type of caution so that people understand those risks.

But when we look at China and we look to the medium and the long term, I mean we're very favorable. I mean we continue to feel very good about the growth. We continue to feel very good about our business. We feel like a lot of the government's focus with their 5-year plan in terms of life sciences and health and safety, a lot of the emerging industries that they're heavily investing in, they all play very well to our portfolio. And then this general theme of automation and digitalization also is a big theme in China as well.

And so -- and as they continue to expand the economic development to the West, I mean we'll -- our industrial business will also benefit. So we continue to feel very strongly about it. But in the short term, there can always be volatility.

Your next question will come from Vijay Kumar with Evercore ISI.

Congrats on a nice [sprint] here. I guess 2 -- one on the Q itself. The gross margin here is sequentially flattish. Historically, you guys have had a very strong Q4 gross margins. So I'm curious, was there any timing element here in Q4? Or what happened to gross margins?

No -- Vijay, this is Shawn. No, I mean, I just -- basically, we just saw the cost inputs increase much faster than what we expected. And it was kind of broad-based in a lot of different cost categories, but I'd probably highlight electronic components as an area that was much higher than the others. And also transportation costs came in higher than expected, which was a little bit of a surprise if you just think about -- like it's not a new topic, and we were already facing cost headwinds in terms of transportation going back to Q4 of last year.

But like we always say, like I think the key in this environment is to make sure that we have the systems in place to be able to monitor these changes so that we can react quickly. And I think you can -- and that's what we're doing. We're highly focused on it as an organization. We're going to see some similar trends in Q1. But I think as you kind of look to the full year, we certainly still feel good about our ability to expand margins.

And as I said earlier before, we still believe we'll expand our gross margin for the full year of 30 to 40 basis points. And then from an operating margin perspective, we expect to be at the high end of our typical guidance, probably around 90 basis points at the midpoint of the guidance.

That's helpful, Shawn. And maybe one for Patrick here. The Q1 guidance here, the comps are really tough. I'm just curious, given the lockdowns here in China, what visibility do you have into those numbers? Or what is driving this Q1 strength? And the guidance raise for the year by 100 basis points, how much of that was pricing versus volume, if you will?

Yes. I mean it's -- look, our confidence in Q1 is driven by demand. We are seeing -- as we said, we are not dramatically impacted by any lockdowns in China right now. There is, of course, a little bit uncertainty moving forward. It might have some impact. But we are pretty confident that -- on the 10% that we have given you for Q1. We see the demand. We see the regions performing, not only Asia Pacific and not only China, it's also the U.S. and Europe is performing as we expect. And that gives us confidence that we will have a solid -- really solid Q1.

In terms of the other questions, it's a little bit of both. There's a little bit of volume, and it's, of course, a little bit of pricing. I mean we don't want to quantify that [perfectly]. Shawn already made comments on pricing, but it's a component of both. We have volume increase, and we have some pricing impact as well.

Your next question will come from the line of Brandon Couillard with Jefferies.

Just a couple for you, Shawn. In terms of pricing for the year, should we think about that as being fairly similar between Lab and Industrial? Or is it more weighted toward one segment or the other? And secondly, in terms of the gross margin outlook, is your expectation that kind of material and transport headwinds fade by the second half? Or is that still a drag on the gross margin line?

Yes, good question, Brandon. So in terms of pricing, probably slightly better on the Lab side than on the Industrial side and -- if I just think about the portfolio. But of course, we'll -- I think we'll have good price increases in both divisions.

In terms of material costs, I think we'll certainly see a drag probably through -- certainly in the first half of the year. I'd like to think by the time we get to Q4, we're not going to see a drag. And so hopefully, there's a little bit of benefit by the time we get to the fourth quarter. But I wouldn't count on too much right now until we see things play out.

And it's true for both. That's true for material, but also transportation. We don't think that [leads] up before the second half.

Yes.

Got you. That's helpful. And then just one follow-up on China in the fourth quarter. Could you break out the Lab versus Industrial businesses for the fourth quarter and kind of what you're seeing for these segments for '22 just within China?

Yes, sure. So our Lab business in the fourth quarter grew in both high 20s. And then our Industrial business in the quarter grew mid-single digit. And kind of for the full year, we're expecting Lab to be probably like low double digit; and then with Industrial, probably like mid-single digit.

Your next question will come from the line of Catherine Schulte with Baird.

I guess, first, you mentioned consumables and services were up 10% in the quarter. How sustainable do you think that growth is going forward? And what's your expectation from those categories in 2022?

Yes. Very good question, Catherine. Thank you. I mean look, I think we have a very good potential in consumables and services. In services, of course, we're also going after our installed base and making sure that those customers who do not have their products on a contract can also switch to contract because it just gives them a more reliable service pattern overall in terms of early maintenance, et cetera.

The 10% we have seen was definitely very strong in Q4. I would say, we -- I -- my expectation for service is it maintains in the high single-digit range for 2022. It's a very profitable business for us, and we are putting a lot of emphasis on making sure that our customers understand the benefit of our services. And we're broadening the service offering over time. So I think this is quite some runway.

Catherine, maybe one additional comment on the consumables is, of course, we won't have the benefit of the COVID testing that we've had in the past. So that could be a little bit of a headwind.

Yes. Okay. Got it. And then in pharma and some other industries, we've seen a bigger push for onshoring and creating redundancy in supply chains that COVID has played out. Where do you think we are in terms of that phenomenon and capacity build out? I'm just curious how much longer you think that could continue to be a tailwind for the market.

I think -- well, I think it will probably continue as it played out in 2021 and 2020 into probably the next 1 or 2 years. That's what we are seeing at least from some of the accounts that we are closely monitoring. And I think it's not only pharma. By the way, we see also some very good momentum in semiconductor where the big facility is coming up now in the United States, where -- a lot of core facilities are coming back to the United States, which is also a very good business for us.

So I think that, again, that will continue from our perspective at least through 2022 or maybe also 2023. It's definitely some good tailwind for the overall market.

Your next question will come from Lu Li with Wells Fargo.

Just want to follow up on the pricing. I think you mentioned 3.5% or even close to 4% for this year. Do you hear any pushback from the customers? And then does that impact your ability to further increase the pricing for next year?

Yes. So just to clarify, so I said, we've -- our guidance previously was 3%, and we're kind of like thinking it's about 3.5% or so for the full year. But we wouldn't be surprised if we're in the 4% kind of a range in the second half of the year. We continue to feel good about our ability to pass on price when we need to when we face these inflationary challenges. And I think we'll continue to do that as market conditions change.

Got it. Another question on the 7% of growth guidance. Does that change your long-term growth outlook? Like should we think about like 7% going forward?

Very good question. Maybe I'll start with some backdrop. We believe we have strengthened our competitive position throughout the pandemic and tend to believe that we are coming out of COVID stronger. We have a very strong foundation across many businesses. We have market-leading positions. We have an excellent product portfolio and a global service network. I think we are able to adapt our sales and marketing tools and techniques to the new environment. And as a result, we continue to gain share, as we mentioned it many times, despite a challenge in these environments.

Our markets nicely rebounded in 2021 and have worked very effectively to capitalize on this growth. Now looking forward, I still think you should think about us as a mid-single-digit growth on an organic basis in the midterm. That's about the dimension that we also think about it.

It, of course, will depend on how the underlying market performs. If it goes back to where it has been pre-pandemic, I think that's the right range we are thinking right now. Of course, if there is momentum in the market, we will -- again, our goal is to grow above our underlying market. But I would like you to think still in mid-single digits.

At this time, there are no further questions in queue. I would now like to turn the call back over to Mary Finnegan for any closing remarks.

Thank you. And I just have 2 additional comments before I let you go for the night. First, we anticipate holding an investor meeting at our facility in Boston on Monday, November 7. We'll come back to you with more details in the coming months, but wanted to mention it to you now as you plan your calendars for this year.

Second, we are happy to announce that Adam Uhlman has recently joined our Investor Relations team. He was formerly a senior equity research analyst at the Cleveland Research Company. Adam will take over the lead in Investor Relations later this year as I will retire towards the end of 2022. It's great to have Adam onboard, and I look for -- please join me in welcoming him, and I look forward to introducing him to you in due time.

For the time being, please continue to direct your Investor Relations matters to me. As always, if you have any questions, please don't hesitate to reach out. Take care, everybody. Bye-bye.

Bye-bye.

This concludes today's conference call. Thank you for participating. You may now disconnect.